Compassionate drug use (CDU) is a topic of debate in the scientific community characterized by a lack of information, especially in the onco-hematology area.
Aim
The Compass-O study aimed to provide updated data on CDU of onco-hematological drugs for the period 2016–2021.
Method
Compass-O is a retrospective observational study with data obtained from 7 Italian Units for cytotoxic drug preparations (Unità Farmaci Antiblastici, UFA). Drugs and Therapeutic Indications (TI) were described separately and as drug-TI combinations, providing the mean Patients Per Year (mPPY) and the Years of Use (YoU).
Results
A total of 783 requests of CDU were retrieved, referring to 156.3 mPPY (max: 272 in 2021; min: 84 in 2018). The 52.2% of subjects was female, and the 63.2% aged >60 years. A total of 709 (90.5%) CDUs referred to solid tumors and 74 (9.5%) to liquid tumors. CDU referred to 93 drug-TI combinations. The most recurrent drug-TIs were nivolumab-lung carcinoma (mPPY: 36.5; YoU: 2) for solid tumors, and azacytidine-acute myeloid leukemia (6.0; 1) for liquid tumors. The most frequent TIs were lung carcinoma (45.7; 6) and breast cancer (37.0; 4) for solid tumors, and chronic lymphocytic leukemia (5.0; 2) and multiple myeloma (4.7; 6) for liquid tumors.
Conclusion
Compass-O provided an updated framework of the CDU in onco-hematology, showing its large-scale phenomenon and the relevance of UFA as a data source, underlining the need for a national observatory to monitor CDU.
WatsonT. A global perspective on compassionate use and expanded access. Ther Innov Regul Sci [Internet]2017; 51: 143–145.
2.
WasserJSGreenblattDJ. Applying real-world data from expanded-access (“compassionate use”) patients to drug development. J Clin Transl Sci [Internet]2023; 7: e181.
3.
CaplanALTeagardenJRKearnsL, et al.Fair, just and compassionate: a pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials. J Med Ethics [Internet]2018; 44: 761–767.
PilunniDNavarraP. Compassionate drug uses in Italy. Analysis of regional and local diffusion. Ann Ist Super Sanita [Internet]2023; 59: 43–50.
6.
JommiCPantelliniFStagiL, et al.The economic impact of compassionate use of medicines. BMC Health Serv Res [Internet]2021; 21: 1303.
7.
PolakTUyl-de GrootCAVan RosmalenJ. PNS410 Data from expanded access programs: treatment first, collection second. An overview of FDA and EMA regulatory approvals. Value Heal [Internet]2019; 22: S835.
8.
GoyalPMathurRMedhiB. Understanding the challenges and ethical aspects of compassionate use of drugs in emergency situations. Indian J Pharmacol [Internet]2020; 52: 163.
9.
AliuPSarpSReichenbachR, et al.International country-level trends, factors, and disparities in compassionate use access to unlicensed products for patients with serious medical conditions. JAMA Heal forum [Internet]2022; 3: e220475.
10.
MontanaroNMelisMProniS, et al.Six-year activity on approval of compassionate use of medicines by the Ethics Committee of the University Hospital of Bologna (Italy): time to update rules and recommendations. Eur J Clin Pharmacol [Internet]2017; 73: 479–485.
11.
GuoloFFianchiLMinettoP, et al.CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J [Internet]2020; 10: 96.
12.
PilunniDDaloisioVCampopianoR, et al.Compassionate drug uses and saving for the national health system: the case study of Fondazione Policlinico Gemelli. Eur Rev Med Pharmacol Sci [Internet]2021; 25: 6365–6377.
13.
Dell’AnnoIDondiLEspositoI, et al.The early access and the potential cost savings by the compassionate use of onco-haematological drugs: results from the Italian study Compass-O. Clin Drug Investig [Internet]2024; 44: 577–586.
FontanalsSEsteveAGonzálezA, et al.Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: a retrospective study from a comprehensive cancer institution. Cancer Med [Internet]2023; 12: 17112–17125.
16.
PolakTBCucchiDGJSchelhaasJ, et al.Results from expanded access programs: a review of academic literature. Drugs [Internet]2023; 83: 795–805.
MaurilloLVendittiASpagnoliA, et al.Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer [Internet]2012; 118: 1014–1022.
19.
ThandraKCBarsoukASaginalaK, et al.Epidemiology of lung cancer. Contemp Oncol (Poznan, Poland) [Internet]2021; 25: 45–52.
BerbenLFlorisGWildiersH,et al.Cancer and aging: two tightly interconnected biological processes. Cancers (Basel) [Internet]2021; 13: 1–20.
22.
FeitNZGoldmanDASmithE, et al.Use, safety, and efficacy of single-patient use of the US food and drug administration expanded access program. JAMA Oncol [Internet]2019; 5: 570–572.
23.
MascoloASportielloLRafanielloC, et al.Do immune checkpoint inhibitors share the same pharmacological feature in the risk of cardiac arrhythmias?Biomed Pharmacother2023; 164: 114912.
24.
JorisSPietersTSibilleA, et al.Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: results from the Belgian compassionate use program. J Geriatr Oncol [Internet]2020; 11: 796–801.
25.
RuggieroRFraenzaFScavoneC, et al.Immune checkpoint inhibitors and immune-related adverse drug reactions: Data from Italian pharmacovigilance database. Front Pharmacol [Internet]2020; 11: 830.
26.
GrivasPBarataPCMoonHH, et al.Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study. American Society of Clinical Oncology 2024; 42: 697–697.
27.
AntonuzzoLMaruzzoMDeGU, et al.READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). American Society of Clinical Oncology 2023; 41: 469–469.
28.
SchreiberARO’BryantCLKabosP,et al.The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan. Expert Rev Anticancer Ther [Internet]2023; 23: 1061–1069.
29.
VermaSMilesDGianniL, et al.Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med [Internet]2012; 367: 1783–1791.
30.
HurvitzSAHeggRChungWP, et al.Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet [Internet]2023; 401: 105–117.
31.
ModiSJacotWYamashitaT, et al.Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med [Internet]2022; 387: 9–20.
32.
TarantinoPTolaneySMCuriglianoG. Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. Ann Oncol [Internet]2023; 34: 949–950.
33.
ThépotSItzyksonRSeegersV, et al.Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol [Internet]2014; 89: 410–416.
34.
de la RubiaJAlonsoRClaveroME, et al.Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Results of the compassionate use or the expanded access program in Spain. Cancers (Basel) [Internet]2023; 15: 2964.
35.
MascoloADi NapoliRBalzanoN, et al.Which is the top player for the cardiovascular safety? Ibrutinib vs. obinutuzumab in CLL. Front Pharmacol [Internet]2023; 14: 1229304.
36.
BoucletFCallejaADilhuydyMS, et al.Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. Ann Hematol [Internet]2021; 100: 987–993.
